These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 9489824)

  • 21. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Apr; 24(4):663-5. PubMed ID: 9101498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis.
    Hasegawa M; Sato S; Ihn H; Takehara K
    Rheumatology (Oxford); 1999 Jul; 38(7):612-7. PubMed ID: 10461473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
    Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
    Nishijima C; Sato S; Takehara K
    J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Takehara K; Sato S
    Ann Rheum Dis; 2004 May; 63(5):583-7. PubMed ID: 15082492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
    Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
    Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection.
    Migita K; Abiru S; Maeda Y; Daikoku M; Ohata K; Nakamura M; Komori A; Yano K; Yatsuhashi H; Eguchi K; Ishibashi H
    Hum Immunol; 2006; 67(1-2):27-32. PubMed ID: 16698422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
    Ogawa F; Shimizu K; Muroi E; Hara T; Hasegawa M; Takehara K; Sato S
    Rheumatology (Oxford); 2006 Jul; 45(7):815-8. PubMed ID: 16449367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
    Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
    Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis.
    Crilly A; Hamilton J; Clark CJ; Jardine A; Madhok R
    Rheumatology (Oxford); 2003 Nov; 42(11):1295-8. PubMed ID: 12867583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.
    Hirota H; Izumi M; Hamaguchi T; Sugiyama S; Murakami E; Kunisada K; Fujio Y; Oshima Y; Nakaoka Y; Yamauchi-Takihara K
    Heart Vessels; 2004 Sep; 19(5):237-41. PubMed ID: 15372299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD.
    Memoli B; Grandaliano G; Soccio M; Postiglione L; Guida B; Bisesti V; Esposito P; Procino A; Marrone D; Michael A; Andreucci M; Schena FP; Pertosa G
    J Am Soc Nephrol; 2005 Apr; 16(4):1099-107. PubMed ID: 15716332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
    Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
    Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis.
    van Bon L; Popa C; Huijbens R; Vonk M; York M; Simms R; Hesselstrand R; Wuttge DM; Lafyatis R; Radstake TR
    Ann Rheum Dis; 2010 Aug; 69(8):1539-47. PubMed ID: 20498209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.
    Wuttge DM; Wildt M; Geborek P; Wollheim FA; Scheja A; Akesson A
    Arthritis Res Ther; 2007; 9(5):R85. PubMed ID: 17784951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
    Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.